New Delhi:

新德里：

Jubilant Pharmova

优时比制药

on Tuesday said it has appointed

周二表示已任命

Daniel J O'Connor

丹尼尔·J·奥康纳

as the CEO of its proprietary novel drugs business.

作为其专有新药业务的首席执行官。

O'Connor brings more than 30 years of leadership experience in biotechnology and oncology, with a proven record of creating value around differentiated, IP-rich platforms, the company said in a statement.

该公司在一份声明中表示，奥康纳在生物技术和肿瘤学领域拥有超过30年的领导经验，有着围绕差异化、富含知识产权的平台创造价值的可靠记录。

Most recently, he served as CEO of

最近，他担任了首席执行官

Ambrx Biopharma

安博生物制药

, where his leadership drove a significant increase in company valuation, culminating in its successful acquisition, it added.

在他的领导下，公司估值显著提升，最终成功被收购，声明补充道。

'We are delighted to welcome Dan as we advance our mission of building a clinical-stage therapeutics company focused on developing innovative therapies across multiple

“我们很高兴欢迎丹的加入，因为我们正在推进建立一家临床阶段治疗公司，专注于开发多种创新疗法的使命

cancer indications

癌症适应症

,' its chairman Shyam S Bhartia said.

“其董事长Shyam S Bhartia表示。

Jubilant

欢欣鼓舞的

Therapeutics Inc. is a clinical-stage biopharmaceutical company developing precision oral medicines with enhanced therapeutic index to address unmet medical needs in oncology and autoimmune diseases for genetically defined patients.

Therapeutics Inc. 是一家临床阶段的生物制药公司，专注于开发具有增强治疗指数的精准口服药物，以满足肿瘤学和自身免疫疾病领域中基因定义患者的未满足医疗需求。

Add

添加

as a Reliable and Trusted News Source

作为一个可靠和值得信赖的新闻来源

Add Now!

立即添加！

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)